



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/086,294	02/28/2002	Loretta Nielsen	016930-003712US 3210		
20350 . 7	590 10/06/2004	EXAMINER			
TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834			ASHEN, JON	ASHEN, JON BENJAMIN	
			ART UNIT	PAPER NUMBER	
			1635		

DATE MAILED: 10/06/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		10/086,294	NIELSEN ET AL.			
		Examiner	Art Unit			
		Jon B. Ashen	1635			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
THE - Exte after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.1. SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply of period for reply is specified above, the maximum statutory period with the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tim  y within the statutory minimum of thirty (30) days  vill apply and will expire SIX (6) MONTHS from  Cause the application to become ABANDONE	tely filed  s will be considered timely.  the mailing date of this communication.			
Status						
1)	1)⊠ Responsive to communication(s) filed on <u>15 March</u> 2004.					
	This action is <b>FINAL</b> . 2b) This action is non-final.					
3)[						
Disposit	ion of Claims					
5) 6) 7)	Claim(s) 1,3-5,9-22,25-40,78 and 79 is/are per 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1,3-5,9-22,25-40,78 and 79 are subjected.	vn from consideration.	quirement.			
Applicati	on Papers					
9) The specification is objected to by the Examiner.						
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority u	ınder 35 U.S.C. § 119					
12) [ ] a)[	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the prioric application from the International Bureau see the attached detailed Office action for a list of	have been received. have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No d in this National Stage			
Attachment	r(s)					
_	e of References Cited (PTO-892)	4) Interview Summary (	PTO-413)			
2) 🔲 Notice 3) 🔲 Inforn	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	e			

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 3-5, 18-40 and 78-79, drawn to a method of treating mammalian cancer cells comprising contacting said cells with a p53 tumor suppressor protein and a microtubule affecting agent, classifiable in class 514, subclass 2.
  - II. Claims 3-5, 9-40 and 78-79, drawn to a method of treating mammalian cancer cells comprising contacting said cells with a nucleic acid encoding p53 and a microtubule affecting agent, classifiable in class 514, subclass 44.
- 2. Claim 1 link(s) inventions I and II. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claim I. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional

Application/Control Number: 10/086,294

Art Unit: 1635

application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

The inventions are distinct, each from the other because of the following reasons:

3. Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

Invention I is a method of treatment comprising contacting cells with a protein.

Invention II is a method of treatment comprising contacting cells with a nucleic acid.

Each method utilizes a patentably distinct product. In the instant case the different inventions are not disclosed as capable of use together and have different modes of operation. Invention I operates by the activity of the administered protein as it interacts with the biochemical machinery of the contacted cell. Invention II operates by gene expression or antisense inhibition, that being the activity of the administered nucleic acid as it interacts with the biochemical machinery of the contacted cell.

Furthermore, searching inventions I and II together would impose a serious search burden. In the instant case, prior art searches of each method are not coextensive. Search of each of these inventions would require different key word searches in divergent patent and non-patent literature databases and would require, at least, searches of distinct method steps related to the administration of either proteins

or nucleic acids. These searches would then require subsequent in-depth analysis of all relevant prior art literature, placing a serious burden on the Office in terms of both search and examination. As such, it would be burdensome to perform examination of the inventions of groups I and II together.

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jon B. Ashen whose telephone number is 571-272-2913. The examiner can normally be reached on 7:30 am - 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on 571-272-0670. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has

Art Unit: 1635

been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

JOHN L. LEGUYADER SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600